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with breast cancer in the UK NHS. METHODS: A previously published decision tree
model was populated and developed with the Vial et. al. and Brown et. al. trial data
to assess the cost-effectiveness of using branded Taxotere®versus its generic coun-
terpart docetaxel from the UK NHS perspective. RESULTS: If the branded Taxotere®
was promoted as the first-line therapy, it would cost the UK NHS £411.54 per vial
per patient with 0.434 QALY (Quality-Adjusted Life Years) gain compared to £412.98
with 0.418 QALY gain if the generic docetaxel was promoted instead and failed the
therapy. Although the acquisition cost of docetaxel is more than 50% less than that
of Taxotere®, promoting the generic docetaxel based on its lower acquisition cost,
only, would result in increasing the total health care cost compared to Taxotere®.
CONCLUSIONS: Based on the decision tree model generated in this study, promot-
ing the branded Taxotere® is more cost-effective compared to its generic counter-
part docetaxel. This should be considered for implementation in practice and for
future guidelines.
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COST-EFFICACY ANALYSIS OF LICENSED DRUGS FOR THE TREATMENT OF
METASTATIC CASTRATE RESISTANT PROSTATE CANCER POST DOCETAXEL
BASED ON HOSPITAL DRUG EVALUATION METHODOLOGY IN SPAIN
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OBJECTIVES: To estimate which is the dominant treatment between the only two
drugs that had been able to demonstrate overall survival (OS) improvements in
patients with metastatic castrate resistant prostate cancer (mCRPC) that have pro-
gressed on or after docetaxel treatment, and that were approved by the EMA in 2011
(AA by accelerated procedure): cabazitaxel (CBZ) and abiraterone acetate (AA),.
METHODS: We replicated the methodology most commonly used by Spanish hos-
pitals to estimate the cost-efficacy of oncologic drugs (OS gains and incremental
costs vs. those of comparators) by: (i) taking the perspective of the Spanish NHS (ii)
estimating treatment costs based on the product labels (i.e. main medication, co-
medication, premedication, and primary prophylaxis) at ex-factory prices, and the
cost of administering such medications; and (iii) the OS data from the respective
pivotal phase III trials: for CBZ vs. mitoxantrone prednisone (MP) OS was 15.1 vs.
12.7 months. For AA vs. placebo prednisone (PP) OS was 15.8 vs. 11.2. Input for the
base case analysis comes from Phase III randomized clinical trials and from pub-
licly available cost data. Sensitivity analysis was performed on: (i) length of treat-
ment; (ii) median OS; and (iii) G-CSF usage and drug administration costs.
RESULTS: In our base case scenario the cost per cycle of CBZ was 4,711.52€ vs.
78.20€ for MP. The cost per cycle of AA was 3,179.26€ vs. 11.85€ for PP. Treatment
costs difference for CBZ vs. MP is 27,799.93€ (range 13,665.36€ – 46,646.01€) and for
AA vs. PP is 25,386.71€ (range 12,669.65€ - 38,103.76€). OS gain is 2.4 months for CBZ
and 4.6 months for AA. CONCLUSIONS: In Spain, based on local hospital method-
ology, AA would be the dominant alternative (higher OS gain and lower incremen-
tal cost) to treat mCRPC patients that have progressed on or after a docetaxel based
regime.
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OBJECTIVES: In Germany, health economic studies are increasingly based on
health insurance claims data analysis. Such data offer a wide range of scientific
applications, especially when focusing on the assessment of resource utilization
patterns and costs. The objective of our study was to estimate the direct health care
costs of three frequent types of cancer (colorectal, breast, and prostate cancer) from
a third-party payer perspective using longitudinal data from a German statutory
health insurance fund and employing a matched pairs design. METHODS: Our
analysis is based on administrative data of a German sickness fund covering a
5-year period (2005-2009). A total of 42,085 cancer patients were included. Disease-
specific costs were estimated by matching cancer patients to counterparts without
the particular condition and subsequently comparing the costs of the two groups.
One-to-one matching was performed by application of the propensity score
method to balance patient characteristics among the cancer groups and non-can-
cer controls. The cost categories considered in this study included prescription
drug costs, outpatient visit costs, and hospitalization costs. RESULTS: The mean
cancer-associated 5-year costs per patient amounted to €5,429 for colorectal can-
cer, €3,200 for breast cancer, and €5,350 for prostate cancer. The average disease-
attributable costs of the first year following diagnosis were €8,750, €4,300, and
€4,750 for colorectal, breast and prostate cancer, respectively. Corresponding ex-
cess costs of the last year of life were €15,900, €10,950, and €14,750. Costs associated
with hospitalization accounted for a major part of the total disease-specific costs
(up to 80%). CONCLUSIONS: This cost-of-illness study based on claims data anal-
ysis confirms the high economic burden of colorectal, breast, and prostate cancer.
Most of the costs occurred in the initial and terminal treatment phases. Inpatient
treatment was found to be the main cost driver.
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Incidence of penile cancer in Europe is slightly increasing. Survival rates in penile
cancer are good, however, there is little research into treatment costs.OBJECTIVES:
To estimate the cost of treating penile cancer in English hospitals, using data from
the HES database. This investigation is part of a wider project aimed at quantifying
the total economic burden of penile cancer in the UK. METHODS: Inpatient admis-
sions for penile cancer between the years 2006/07 to 2010/11 were retrospectively
analysed. Data was obtained from HES, a database covering English hospital activ-
ity, with inpatient episodes aggregated into spells of care associated with a specific
Healthcare Resource Group (HRG). The HRGs were linked to costs from the UK
National Tariff in order to calculate the average annual and per patient payments
for inpatient treatment of penile cancer, as per the NHS Payment by Results frame-
work. Where necessary, costs were supplemented by expert opinion and other
published cost estimates. A limited amount of HES data on outpatient consulta-
tions was also collected and analysed. RESULTS: The mean annual amount paid to
English hospitals for inpatient treatment of invasive penile cancer in England was
estimated to be £2,391,700, with a further £189,106 paid for carcinoma in situ of the
penis. Per inpatient, mean costs were approximately £3,743 and £1,323 for invasive
penile cancer and carcinoma in situ, respectively. Outpatient costs were consider-
ably lower, due to the majority of care being delivered in an inpatient setting and
issues with HES outpatient data collection. Further research into outpatient costs is
currently ongoing. CONCLUSIONS: The burden of penile cancer in the UK has cost
implications, the full extent of which cannot yet be ascertained due to underesti-
mation of outpatient costs. Any preventive intervention aimed at decreasing this
burden should be carefully considered.
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OBJECTIVES: To estimate the costs associated with melanoma for Russia in 2009.
METHODS: Prevalence-based cost-of-illness analysis (COI) was performed from
the payer’s point of view (national and regional governments). Direct medical costs
(hospital and outpatient services and drugs provided in outpatient care), non-med-
ical costs (monetary payments in social benefits) and indirect costs (projected pro-
ductivity loss due to sickness and disability) associated with melanoma in Russia in
2009 were calculated. We obtained the data for analysis from the national statis-
tics, regional cancer and prescription registries, expert panel interviews and liter-
ature. The costs were calculated for the total population of melanoma patients in
Russia. To calculate direct medical costs, we used national reimbursement rates
per unit of care (1 hospital day or 1 visit to an out-patient oncology clinic) and
regional data on melanoma drug costs. To access non-medical costs, we used data
on social benefits expenditures. Indirect costs were estimated with friction costs
method. RESULTS: The total costs of melanoma in Russia in 2009 was 771,2 million
RUR (€18,8mln), or 11 314 RUR (€275,9) as average cost per patient per year. Almost
half of total costs (48.3%) occur in patients during the 1st year after diagnosis. The
direct medical costs accounted for 52,41% of total spending, direct non-medical
costs – for 34,9%, and indirect costs – for 12,69%. Direct medical costs represented
72,8% of total spending in melanoma patients within the 1st year after the diagno-
sis; during the subsequent years after the diagnosis this number reduces to 34,2%.
CONCLUSIONS: Our analysis demonstrates that the most significant part of med-
ical costs for melanoma occur during the 1st year after diagnosis that corresponds
with the results of other COI studies in oncology; in subsequent years the main
costs are outside the scope of health care system.
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OBJECTIVES:Despite the considerable disease burden of ovarian cancer (OC), there were
no cost studies in Central and Eastern Europe. This study aimed to describe treatment
patterns, health care resource utilization and costs associated with OC in Hungary, Po-
land, Serbia and Slovakia. METHODS: Overall clinical practice for management of
epithelial ovarian cancer was investigated through a three-round Delphi panel
consisting of 15 clinical experts. Experts completed a survey based on patient re-
cords (N1,542). The survey was developed based on clinical guidelines and the
FIGO Annual Report. Means, ranges and outlier values were discussed with the
experts during a telephone interview. Finally, consensus estimates were obtained
in face-to-face workshops. Based on these results, overall cost of OC was estimated
using a Markov model. RESULTS: The patients included in the chart review were
followed from pre-surgical diagnosis and in each phase of treatment, i.e. primary
surgical staging and surgery, chemotherapy and chemotherapy monitoring, fol-
low-up and palliative care. Overall treatment patterns were similar but regimens in
second and subsequent lines of chemotherapy varied across the countries. The
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5-year overall cost per patient was €13,900-€17,200 in Hungary, €16,300-€18,300 in
Poland, €8,900-€9,600 in Serbia and €12,500-€15,700 in Slovakia (presented in ranges
due to uncertainty around palliative care). Chemotherapy-associated costs ac-
counted for 59-71% of the total, followed by primary surgical treatment (13-23%)
and palliative care (4-15%). Contribution of drug costs to the overall costs varied
among the countries (in Poland 29%, in Serbia 55% of total costs). CONCLUSIONS:
Given the scarcity of OC cost studies worldwide, these findings may provide a
useful source for clinicians and decision makers in understanding the economic
implications of managing ovarian cancer in Central and Eastern Europe and the
need for innovative therapies.
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OBJECTIVES:Toexaminetheincrementalcostsofchemotherapy-associatedAEsinmBC
METHODS: The PharMetrics Database (2000-2010) was used to identify mBC pa-
tients treated with first- or second-line taxane (paclitaxel or docetaxel) or capecit-
abine-based regimens, with treatment episodes (TEs)30 days. Inverse probability
weighting was used to balance patient characteristics between cohorts with and
without AEs. Incremental costs attributable to AEs were assessed by comparing
costs incurred during TEs with and without AEs and included the following com-
ponents: inpatient, outpatient, emergency room, other medical service, pharmacy
costs, and total health care costs. Sensitivity analyses were conducted to examine
the average monthly costs in patients cohorts stratified by the number and type of
AEs reported during the TEs. RESULTS: 3,222 women (mean age57) received a first-
and/or second-line taxane or capecitabine for mBC. Of the 2,678 1st-line patients, 69.7%
received taxane and 30.3% capecitabine. AEs were commonly seen in patients treated
with first-line taxane (94.6%) and capecitabine (83.7%). On average, the total monthly
incremental cost associated with AEs was 38% higher ($3,547) for taxane and 9% higher
($854) for capecitabine. Inpatient and other drug costs accounted for a majority of the
increasedcosts.Of1,084second-linepatients,66.0%receivedtaxaneand34.0%withcape-
citabine.94.4%ofsecond-linetaxanepatientsand84%ofcapecitabinepatientshadanAE.
The average total monthly incremental cost associated with AEs for taxane was $5,320
and $4,933 for capecitabine (69.5% and 82.9% higher vs. patients without AEs). Differences
in pharmacy costs drove the incremental AE-related costs in taxanes users; inpatient and
outpatient costs accounted for the majority of these costs in capecitabine users. Sensitiv-
ity analyses showed a clear trend of an increasing economic burden with the number of
AEs. CONCLUSIONS: Chemotherapy-related AEs are associated with a substantial
economic burden primarily explained by increased inpatient, outpatient, and
pharmacy costs.
PCN52
ENGLISH HOSPITAL COSTS FOR ANAL CANCER: PRELIMINARY RESULTS FROM
AN INVESTIGATION USING HOSPITAL EPISODES STATISTICS (HES)
Tempest MJ1, Keeping ST2, Thurston S1, Carroll SM3
1Pharmerit Ltd, York, UK, 2Sanofi Pasteur MSD, Maidenhead, Berkshire, UK, 3Sanofi Pasteur
MSD, Maidenhead, UK
There is some evidence that the annual number of patients diagnosed with anal
cancer in the UK is increasing. Such a rise could potentially have important health
and economic consequences. OBJECTIVES: To estimate hospital treatment costs
for anal cancer in England, based on data from the HES database, as part of a wider
study investigating the total economic burden of anal cancer in the UK.METHODS:
Inpatient admissions for anal cancer between the years 2006/07 to 2010/11 were
retrospectively analysed. Data was obtained from HES, a database covering English
hospital activity, with inpatient episodes aggregated into spells of care associated
with a specific Healthcare Resource Group (HRG). The HRGs were linked to costs
from the UK National Tariff in order to calculate the average annual and per inpa-
tient payments for treatment of anal cancer, as per the NHS Payment by Results
framework. Where necessary, costs were supplemented by expert opinion and
other published cost estimates. A limited amount of HES data on outpatient con-
sultations was also collected and analysed. RESULTS: In England, the average an-
nual payments for inpatient care associated with anal cancer are estimated to total
£7,754,219 (males  £2,930,360, females  £4,823,859). This translated to a mean
annual cost per inpatient of £4,605 and £5,232 for males and females respectively.
Outpatient costs were lower across both genders with annual payments for outpa-
tient care estimated at £184,479 for males and £286,686 for females. This is likely to
be a significant underestimate due to coverage issues with the HES outpatient
dataset on account of local variation in the sources of funding for certain treat-
ments. Further research into outpatient costs is currently ongoing.CONCLUSIONS:
Despite the significant underestimation of the outpatient costs, these results sug-
gest anal cancer places a significant health and economic burden on the English
NHS.
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OBJECTIVES: To assess the management and associated lifetime costs in MM pa-
tients as from the diagnosis of unresectable metastatic disease until death.
METHODS: A retrospective patient chart review was performed at the Antwerp
University Hospital to obtain data on medical consumption related to the manage-
ment of unresectable metastatic MM (umMM). A complete registry of all MM pa-
tients who visited the hospital between 2007 and May 2012 was compiled. Eligible
for this retrospective chart review were patients with umMM with sufficient data
available and who deceased before May 2012. Data on demographics, disease char-
acteristics and management of umMM were collected. Direct costs were calculated
by multiplying each item of resource use with its unit cost (2012, € ) using the
Belgian public health care payer’s perspective (PHCP) and patient’s perspective.
Average (bootstrap 95%CI) overall costs per patient were calculated. RESULTS: Out
of 148 registered MM patients, 29 were eligible and included in this chart review.
The median overall survival time in all patients was 6.0 months. 86% (n25) of
patients were treated by systemic treatment(s) of which 24% (n6) received up to 4
different treatment lines. Dacarbazine was administered in all patients as a single
agent or in combination therapy. 4 patients received 1 to 4 cycles of ipilimumab
treatment. 53 (43%) of the 123 hospitalizations were for chemotherapy administra-
tion. The mean overall cost per patient was €31,637 (bootstrap 95% CI:23,993-
39,891), of which € 30,585 € (95%CI: 23,154-38,784) was reimbursed. The PHCP cost
was driven by hospitalization costs and systemic treatments costs both represent-
ing 33% of total cost. CONCLUSIONS:Management of umMM result in considerable
costs for the PHCP mainly driven by systemic treatment costs and hospitalization
costs. It would be interesting to extend this study in a broader population.
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OBJECTIVES: This review was conducted to assess the economic burden of pancre-
atic cancer (PC) in Europe. METHODS: Systematic search of Embase® and MED-
LINE® databases was conducted from January 2002 to June 2012 to identify eco-
nomic studies on PC in Europe. English language studies, regardless of design and
intervention were included. Eligibility of trials was assessed by two reviewers with
any discrepancy reconciled by a third, independent reviewer. RESULTS: Of the 97
retrieved citations, seven met pre-defined inclusion criteria. Four studies were
cost-analyses while other three were cost-minimisation, cost-utility, and cost-ben-
efit analysis, respectively. In Europe, the predicted PC mortality varied between
6.6-8.2/100,000 men and between 4-5.7/100,000 women in 2012. In Sweden, the
direct costs/patient/month associated with PC rose from €1578 in 2001 to €3103 in
2002-2005 and then to €6590 in 2009. In 2009, the major contributors of this direct
cost were hospitalisations (€4670), surgery (€719), and chemotherapy (€258). The
mean total cost of illness/patient for PC in Germany was €31,375 (cost years 2000-
2003), where direct cost was responsible for 90% of this total value and the remain-
ing 10% was contributed by indirect costs including loss of productivity due to
days-off work. In 2009, the estimated cost/patient associated with loss of produc-
tivity due to absenteeism was €6077 in Sweden. Upon assessment of curative re-
section cost for PC per patient in Sweden, it was found to be about €39,000 in 2009.
The mean costs per patient associated with the use of diagnosis of PC were $1925 in
Switzerland (2004), $1249 in Spain (2001), and €1545 in Sweden (2001).
CONCLUSIONS: Although limited data is available, a trend in increase of fiscal
burden of PC was observed. The major contributors of this burden were surgery,
hospitalisations, chemotherapy, and loss of productivity. Therapies that prevent or
delay disease progression could reduce this burden.
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OBJECTIVES: Chronic lymphocytic leukemia (CLL) is a slowly progressing but mor-
tal disease that imposes a high economic burden on sickness funds and society.
The objective of this study is to analyze and compare the direct and indirect costs
of CLL in Germany from the perspective of both sickness funds and society, and to
analyze the burden of the disease. METHODS: Using a database of 7.6 million
enrolled individuals, we identified 4198 CLL patients in 2007 and 2008. Costs attrib-
utable to CLL were estimated using a case-control design, with a control group of
150 individuals randomly drawn by age and sex for each CLL observation. We used
GEE and count data models to test for differences in costs and health care
utilization. RESULTS: The cost attributable to CLL per prevalent case amounts to
€4946 from the payer’s perspective, and €7910 from that of society. Inpatient stays
and pharmaceutical consumption are the main cost drivers of the disease. The
burden of disease in Germany is estimated to be approximately €201 million per
year from the sickness fund perspective (€322 million from the societal
perspective). CONCLUSIONS: Compared with common diseases such as diabetes
or COPD, the economic burden of CLL is considerably lower. However, the cost of
treatment per case is about twice as high as for these common diseases, even
though treatment is performed in later stages only. Owing to new health care
technologies, an ageing population, and an increasing incidence, it is likely that the
burden of the disease will continue to grow.
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